ESMO Guidelines 2022 - risk reduction and screening in hereditary breast-ovarian cancer syndromes

Various methods for risk-reduction and screening for breast, ovarian and prostate cancers in BRCA1 and BRCA2 mutation carriers and for pancreatic cancer in STK11 mutation carriers are presented according to the latest ESMO clinical practice guideline from 2022.